Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Wataru Fukuokaya(Jikei University School of Medicine), Tatsuya Shimomura(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Shintaro Narita(Akita University), Hidetsugu Takahashi(Jikei University School of Medicine), Katsuki Muramoto(Jikei University School of Medicine), Shingo Hatakeyama(Hirosaki University), Keiichiro Mori(Jikei University School of Medicine), Tomonori Habuchi(Akita University)
Cited by 19
Related Papers
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract.
|PubMed|1998|176
Endothelial Heparan Sulfate Controls Chemokine Presentation in Recruitment of Lymphocytes and Dendritic Cells to Lymph Nodes
|Immunity|2010|165
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
|Clinical Cancer Research|2019|129